PRME
HealthcarePrime Medicine, Inc. · Biotechnology · $540M
What is Prime Medicine, Inc.?
Prime Medicine is a Cambridge-based biotechnology company focused on delivering genetic therapies through a proprietary gene editing platform. Its approach targets the root cause of diseases at the DNA level, positioning it at the frontier of precision medicine.
Prime Medicine develops Prime Editors — a class of gene editing tools that combine a Cas protein fused with a reverse transcriptase enzyme. Paired with a pegRNA that directs the editor to a precise genomic location, the system can make targeted corrections to DNA without the double-strand breaks associated with earlier editing approaches. The company's revenue model is pre-commercial, relying on partnerships and capital raises as it advances its pipeline toward clinical milestones.
Prime Medicine was incorporated in 2022 and is headquartered in Cambridge, Massachusetts.
- Prime Editor protein platform for precise DNA correction
- pegRNA guides targeting specific genomic locations
- Pipeline of genetic therapy candidates across disease areas
- Proprietary gene editing technology licensed for research
Is PRME a Good Stock to Buy?
UQS Score rates PRME as Below Average overall, reflecting the early-stage nature of its business despite meaningful scientific promise.
The Growth pillar stands out as the clearest bright spot — Prime Medicine operates in a rapidly expanding gene editing space with a differentiated platform that could address diseases with few existing treatment options. The Risk pillar also registers as Good, suggesting the company's financial structure and operational risk profile are relatively manageable for a pre-commercial biotech.
Both the Quality and Moat pillars score as Weak, consistent with a company that has yet to generate commercial revenue or establish durable competitive barriers. Valuation is rated Elevated, meaning the current market price reflects significant future expectations.
Pro members can view the complete pillar breakdown and underlying financial metrics for PRME on the full analysis page. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PRME pay dividends?
No — Prime Medicine, Inc. does not currently pay a dividend.
Prime Medicine does not pay a dividend, which is typical for pre-commercial biotechnology companies. Available capital is directed toward research, platform development, and clinical advancement rather than shareholder distributions. Investors in PRME are generally seeking long-term value creation through pipeline progress rather than income.
When does PRME report earnings?
Prime Medicine reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-commercial biotech, quarterly reports focus primarily on cash runway, operating expenses, and pipeline updates rather than revenue growth. Progress on clinical programs and partnership developments tend to be the key narrative drivers each quarter.
For the most recent quarter's results and management commentary, visit Prime Medicine's investor relations page directly.
PRME Price History
-79.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
PRME Long-term Outlook
Prime Medicine's Growth pillar rating of Strong reflects the significant long-term opportunity embedded in its gene editing platform. However, the path from scientific innovation to commercial product is long and uncertain. The Elevated Valuation pillar suggests the market has already priced in a degree of future success, leaving limited margin for setbacks. The Good Risk rating provides some reassurance that near-term financial stability is not an immediate concern.
Growth drivers
- Expanding clinical pipeline across multiple genetic disease indications
- Growing industry and academic interest in precision gene editing
- Potential for partnership deals or licensing agreements to accelerate development
Key risks
- Pre-commercial stage means no product revenue to cushion setbacks
- Elevated valuation leaves little room for clinical trial disappointments
- Competitive gene editing landscape with well-funded rivals
PRME vs Peers
Prime Medicine operates in a broader landscape of small-cap biotechnology and specialty pharma companies, each pursuing differentiated therapeutic strategies.
Bright Minds focuses on neuropsychiatric disorders through targeted serotonin receptor compounds, a distinct therapeutic area from Prime Medicine's gene editing approach.
Eton Pharmaceuticals is a commercial-stage specialty pharma company focused on rare pediatric diseases, giving it a revenue profile that contrasts with Prime Medicine's pre-commercial status.
Alpha Tau Medical develops alpha radiation cancer therapy, representing a hardware-based oncology approach rather than genetic medicine.
Frequently Asked Questions
What does Prime Medicine do?
Prime Medicine develops gene editing therapies using its proprietary Prime Editor platform. The technology combines a Cas protein with a reverse transcriptase enzyme, guided by a pegRNA to make precise corrections at targeted DNA locations. The company is pre-commercial and focused on advancing its pipeline toward clinical and eventually commercial milestones.
Does PRME pay dividends?
No, Prime Medicine does not pay a dividend. As a pre-commercial biotechnology company, it reinvests all available capital into research and pipeline development. Dividend payments are not typical for companies at this stage of development.
When does PRME report earnings?
Prime Medicine reports on a standard quarterly schedule. Because it is pre-commercial, reports center on operating expenses, cash position, and pipeline updates rather than revenue figures. Check Prime Medicine's investor relations page for the latest scheduled reporting dates.
Is PRME a good stock to buy?
UQS Score rates PRME as Below Average overall. While the Growth pillar is rated Strong and Risk is rated Good, the Quality and Moat pillars are both Weak, and Valuation is Elevated. The full pillar breakdown is available to Pro members and can help investors weigh these trade-offs in context.
Is PRME overvalued?
The UQS Valuation pillar for PRME is rated Elevated, indicating the current market price reflects significant future expectations relative to the company's present fundamentals. For a pre-commercial biotech, this is not unusual, but it does mean the stock has limited cushion if clinical progress disappoints.
How does PRME compare to its competitors?
Prime Medicine's peers in the small-cap biotech and specialty pharma space — including Bright Minds Biosciences, Eton Pharmaceuticals, and Alpha Tau Medical — each pursue distinct therapeutic strategies. PRME differentiates itself through its gene editing platform, though it remains pre-commercial compared to some peers that have reached revenue-generating stages.
What is PRME's market cap bracket?
Prime Medicine is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and risk relative to large- or mega-cap peers, but also the potential for outsized growth if clinical programs succeed.
Who founded Prime Medicine?
Prime Medicine was founded by scientists with roots in the gene editing research community, drawing on foundational work in prime editing developed at academic institutions. The company was incorporated in 2022. Detailed founding information is publicly available through the company's official disclosures.
Is PRME a long-term quality indicator?
From a long-term quality standpoint, PRME's UQS profile is mixed. The Strong Growth rating reflects the platform's long-term potential, but Weak Quality and Moat scores indicate the company has not yet built the durable financial or competitive foundations associated with high-quality long-term holdings. Pro members can access the full analysis for a deeper view.
What is the main competitive advantage of Prime Medicine?
Prime Medicine's core differentiation lies in its Prime Editor technology, which aims to make precise DNA corrections without introducing double-strand breaks — a limitation of earlier gene editing methods. However, the UQS Moat pillar is currently rated Weak, reflecting that these scientific advantages have not yet translated into durable commercial barriers.
What sector does PRME belong to?
Prime Medicine operates in the Healthcare sector, specifically within biotechnology. It sits at the intersection of genetic medicine and precision therapy, targeting diseases at the DNA level through its proprietary gene editing platform.
Is PRME a growth stock or value stock?
Based on its UQS profile, PRME leans toward the growth category — the Growth pillar is rated Strong, reflecting the long-term opportunity in gene editing. However, the Elevated Valuation rating suggests investors are already paying a premium for that growth potential, which is a common characteristic of early-stage biotech growth stocks.
Unlock Full PRME Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access underlying financial metrics driving each pillar
- ✓Compare PRME against sector peers side by side
- ✓Track pillar changes as new data is released
- ✓Screen for stocks with stronger Quality and Moat ratings
- ✓Get the full analyst view available only to Pro members
Pro Analysis
PRME — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 28.5 | 0.0 | 17.0 | 72.1 | 65.9 | 0.0 | -1.1 |
| Apr 22, 2026 | 29.6 | 0.0 | 17.0 | 72.1 | 73.2 | 0.0 | -3.7 |
| Apr 2, 2026 | 33.3 | 0.0 | 17.0 | 90.1 | 73.2 | 0.0 | — |
PRME — Pillar Breakdown
Quality
— 0.0/100 (25%)Prime Medicine, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 72.1/100 (20%)Prime Medicine, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 65.9/100 (15%)Prime Medicine, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Prime Medicine, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 17/100 (25%)Prime Medicine, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PRME.
Score Composition
Financial Data
More Stock Analysis
How is the PRME UQS Score Calculated?
The UQS (Unified Quality Score) for Prime Medicine, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Prime Medicine, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Prime Medicine, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.